EARLY DETECTION OF SEPSIS AND CANCER
Threat-Agnostic, Host-Response Functional Biomarker Platform
WHO WE ARE
Albutran is an American in vitro diagnostics development company. Our mission is to enable accurate diagnosis of cancer and sepsis, very early, when the disease damage is minimal and treatment is most effective.
Our technology uses electron paramagnetic resonance (EPR) spectroscopy to investigate human serum albumin in patient blood samples.
Analyzing the EPR-detectable biophysical properties of blood serum, Albutran’s in vitro diagnostic system provides the physician with new, critical diagnostic information having higher granularity, preparing him to more effectively optimize patient treatment, patient post-treatment, and patient outcomes.
Disease Diagnostics by Albutran using the EPR-detectable, biophysical properties of blood serum proteins for disease diagnosis of:
-
• Diagnosis (early detection)
• Prognosis
• Treatment management
-
• Diagnosis (early detection)
• Prognosis
• Treatment management
NEWS
Dr. Herbert A. Fritsche (ADLM Hall of Fame; 41 years MD Anderson Cancer Center) joins Albutran as Chief Science Officer.
ADLM Disruptive Technology Award Competition — Albutran application submitted for 2026.
“ATA-test” for Cancer
The ATA-test for cancer is the culmination of Albutran’s identification of biomarkers that accurately detect onset of aggressive, life-threatening cancers, and especially differentiate from non-life-threatening tumors.
Technology
Albutran rapid diagnosis of cancer malignancy employs the Albutran EPR (Electron Paramagnetic Resonance) spectrometer. A 6-minute scan of the patient’s blood serum sample, detects the presence (or absence) of life-threatening growth of malignant cancer in the patient, with a sensitivity of 90% and a specificity of 90% (false negative of 10% and false positive of 10%).
Measured Parameter (DR)
Albumin Conformation Index (the measured, EPR-detectable parameter of human serum albumin for active cancer malignancy)
“ATA-TEST” FOR CANCER
DR less than 1.0 is associated with
Assessment
• onset — early detection of aggressive, life-threatening malignant growth
Assessment
• independent, quantitative confirmation where malignancy is already indicated by other diagnostic methods
Prognosis
• post surgery — active malignant material remains
Prognosis
• trending up over serial measurements — consistent with response to treatment
Prognosis
• ttending down over serial measurements — consistent with inadequate response
DR value greater than 1.0 is associated with
Assessment
• no aggressive malignant signal detected
Surveillance
• trending up over serial measurements — no aggressive malignant signal detected
Regulatory status: The Albutran ATA-test and the EPR AXM-09 analyzer have not been cleared or approved by the U.S. Food and Drug Administration and are not available for sale in the United States. Clinical performance data presented here were generated in studies conducted outside the United States.
“ATA-test” for Sepsis
An effective test for sepsis should diagnose sepsis at the initial stage of the disease - at the stage of accumulation of excess toxins in the blood, before the onset of symptoms that occur after prolonged exposure to toxins in the patient's body.
Technology
Albutran has developed an in vitro blood test that can be performed in 30 minutes, which employs the Albutran EPR (Electron Paramagnetic Resonance) spectrometer. The Albutran test accurately detects the onset of sepsis in a sepsis-risk patient one to two days earlier than current tests. A 3-minute scan of the patient’s blood serum sample, detects the existence (or absence) of beginning sepsis in the patient, with a sensitivity of 80% and a specificity of 80% (false negative of 20% and false positive of 20%).
Measured Parameter (DTE)
Detoxifying Efficiency (as a % - the measured, EPR-detectable parameter of human serum albumin for Toxicity)
“ATA-TEST” FOR SEPSIS
A low value of DTE can be used for
Diagnosis
• onset - very early detection of developing sepsis
Diagnosis
• confirming sepsis indicated by other diagnostic methods
Prognosis
• trending higher - treatment effective; should continue
Prognosis
• trending lower - treatment ineffective; should be modified
A high value of DTE is associated with
Assessment
• no developing sepsis detected at the time of measurement
Prognosis
• trending higher over serial measurements — no sepsis signal detected; consistent with recovery
Regulatory status: The Albutran ATA-test and the EPR AXM-09 analyzer have not been cleared or approved by the U.S. Food and Drug Administration and are not available for sale in the United States. Clinical performance data presented here were generated in studies conducted outside the United States.
TECHNOLOGY
LABORATORY ANALYZER “EPR AXM-09”
Our technology uses electron paramagnetic resonance (EPR) spectroscopy to investigate human serum albumin in patient blood samples.
CONTACT US
Albutran USA, LLC
Lee Smith, PhD.
Katy, TX
(713) 854-6660
lee.smith@albutran.com
General Inquiries
info@albutran.com
Are you a clinical research center interested in collaborating with Albutran on a study? Please contact bd@albutran.com
Our Team
Herbert A. Fritsche, PhD
Chief Science Officer | CLIA Laboratory Director
ADLM Hall of Fame. 41 years Chief of Clinical Chemistry, MD Anderson Cancer Center. Participated in FDA clearance of many serum cancer biomarkers in US clinical use (CEA, AFP, PSA, CA-125, HER2/neu, CTC). Former FDA and NCI consultant. 200+ publications.
Vladimir Muravsky, PhD.
Inventor | Founder | Chief Technology Officer
50 patents. 56 publications (Clinical Chemistry, Hepatology). Designed the EPR AXM-09 analyzer and all ATA-test algorithms. Developed the technology in response to Chernobyl. 45+ years EPR spectroscopy.
Lee Smith, PhD.
General Manager
Cornell BS/MEng. 40+ years international technology transfer (8 BASF Germany→US transfers). Contributing Author, Perry’s Handbook. US Navy veteran, Fleet Intelligence. Leads FDA strategy, BARDA engagement, US manufacturing.
Joseph Gibson, MBA, PhD.
Consultant
Healthcare Business Strategy
© 2026 Albutran USA, LLC. All rights reserved.
Regulatory status: The Albutran ATA-test and the EPR AXM-09 analyzer have not been cleared or approved by the U.S. Food and Drug Administration and are not available for sale in the United States. Clinical performance data presented here were generated in studies conducted outside the United States.